AcrySof® Cachet® Phakic Lens—Engineered for Excellence™

The Future of Phakic Lenses Starts Now

Beyond anything else, a phakic lens must be safe and efficacious. For the past several years, Alcon has been gathering data for our AcrySof® Cachet® Phakic Lens on both fronts. The support for our story is strong and enduring:

  • Proven safety
  • Unique lens design
  • Excellent visual outcomes
  • Trusted heritage

The time has come for you to consider a new phakic lens—the only one that is designed to last.

A lens that maintains endothelial cell density (ECD)

  • Mean annualized percent central ECD loss of 0.41% for the postoperative period, 6 months to 3 years (n=101)
  • Mean annualized percent peripheral ECD loss of 1.11% for the same time period (n=95)
  • Normal endothelial cell loss is 0.6% ± 0.5% per year1

Refractive IOLs

  • Data shown is mean change with lower 90% confidence interval
  • Year 1 and year 2 show gains in ECD
  • Baseline = 6 months post-op

Maintaining healthy ECD levels is one major measure of confidence.

Stable Cell Morphology Further Illustrates the Preservation of Healthy ECD Levels

  • Central and peripheral endothelial cellular shape (mean % hexagonality) was unchanged at all post-op visits through 3 years
  • The cell size distributions (mean coefficient of variation) remained constant during all post-op visits through 3 years

Minimal ECD changes + stable cell morphology = preservation of corneal health

Refractive IOLs

With a Heritage Like No Other

An innovative, angle-supported design. A time-tested lens material. Crafted together, they provide a proven clinical solution for the challenges of maintaining endothelial cell density and avoiding pupil ovalization. The AcrySof® Cachet® Phakic Lens is an outstanding opportunity for your patients with moderate to high myopia to improve their vision.

  • Trusted AcrySof® lens material is designed specially for the eye
  • Over 40 million AcrySof® lenses have been implanted to date
  • From Alcon, the world leader in intraocular lenses

Refractive IOLs


All claims based on clinical study data analysis completed in May 2008 and presented in the CE Technical file. Refer to the Physician’s Directions for Use for more information.

References

  1. Bourne et al. Invest Ophthalmol Vis Sci. Central corneal endothelial cell changes over a ten-year period. 1997;38:779-782.